An Exceptionally Favorable Response to Etoposide and Cisplatin

Cureus
doi 10.7759/cureus.418
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Cureus, Inc.

Related search

Unexpected Favorable Outcome to Etoposide and Cisplatin in a Small Cell Lung Cancer Transformed Patient: A Case Report

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2019English

Treatment With Cisplatin and Etoposide Chemotherapy in Patient With Metastatic Breast Cancer

Journal of Breast Disease
2017English

A Favorable Response to Cisplatin, Pemetrexed and Bevacizumab in Two Cases of Invasive Mucinous Adenocarcinoma Formerly Known as Pneumonic-Type Mucinous Bronchioloalveolar Carcinoma

Internal Medicine
Internal MedicineMedicine
2013English

Drosophila Strain Specific Response to Cisplatin Neurotoxicity

Fly
Insect Science
2018English

Unusual Gastrointestinal and Cutaneous Toxicities by Bleomycin, Etoposide, and Cisplatin: A Case Report With Pharmacogenetic Analysis to Personalize Treatment

EPMA Journal
BiochemistryHealth PolicyDrug Discovery
2017English

Treatment of Metastatic Germ Cell Tumors With Etoposide and Cisplatin as First Line Chemotherapy

Japanese Journal of Urology
Urology
2002English

DCEP (Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin) Is an Effective Regimen for Peripheral Blood Stem Cell Collection in Multiple Myeloma

Bone Marrow Transplantation
TransplantationHematology
2001English

Addition of Intraperitoneal Cisplatin and Etoposide to First-Line Chemotherapy for Advanced Ovarian Cancer: A Randomised, Phase 2 Trial

British Journal of Cancer
Cancer ResearchOncology
2018English

Ixr1 Regulates Ribosomal Gene Transcription and Yeast Response to Cisplatin

Scientific Reports
Multidisciplinary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy